Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Roche / Genentech: Clinical Trials & FDA Approval Profile

Roche / Genentech (South San Francisco, CA / Basel, CH) sponsors 353 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 158 active protocols (65 recruiting now), 131 completed protocols, and 95 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.9%
Median Closed Enrollment vs National (145 pts)186 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Roche / Genentech
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)353
Active Pipeline (Recruiting Now)158 (65)
Completed vs Stopped Early131 / 63 (17.9%)
Median Closed Actual Enrollment186 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals95 (19 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Roche / Genentech
Hospital Research SiteLocationShared Protocols
Asan Medical CenterSeoul100
Samsung Medical CenterSeoul, Gangnam-Gu92
Seoul National University HospitalSeoul84

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Roche / Genentech
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePhase IIIRECRUITING
NCT04302025A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase IIRECRUITING
NCT05199688A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With AquapoPhase IIIRECRUITING
NCT07598396A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisPhase IIRECRUITING
NCT07448038A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation iPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Roche / Genentech Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI